Close
  Indian J Med Microbiol
 

Figure 2: Kaplan–Meier curve depicting overall survival from the day of starting lorlatinib (in months) (number of events – 9). The estimated mean overall survival was 13.6 months (range, 10.6–16.6 months)

Figure 2: Kaplan–Meier curve depicting overall survival from the day of starting lorlatinib (in months) (number of events – 9). The estimated mean overall survival was 13.6 months (range, 10.6–16.6 months)